This phase I trial is evaluating a new oral cancer drug in patients with select advanced solid cancers.
This trial is treating patients with select advanced cancers, including Cutaneous Squamous Cell Carcinoma, Urothelial Cancer, Cervical Cancer, Hepatocellular (Liver) Cancer, Oesophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma and Nasopharyngeal (Nose) Carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
Eligible patients will be assigned to a treatment cohort, depending on their tumour type and treatment history. All enrolled patients will receive either 25mg or 100mg oral INCB099280, once daily or twice daily, on each day of each 28-day cycle.
Recruiting Hospitals Read More